BR112016007816A2 - composições peptídicas inovadoras - Google Patents

composições peptídicas inovadoras

Info

Publication number
BR112016007816A2
BR112016007816A2 BR112016007816A BR112016007816A BR112016007816A2 BR 112016007816 A2 BR112016007816 A2 BR 112016007816A2 BR 112016007816 A BR112016007816 A BR 112016007816A BR 112016007816 A BR112016007816 A BR 112016007816A BR 112016007816 A2 BR112016007816 A2 BR 112016007816A2
Authority
BR
Brazil
Prior art keywords
peptide compositions
innovative
innovative peptide
compositions
things
Prior art date
Application number
BR112016007816A
Other languages
English (en)
Portuguese (pt)
Inventor
Franklin Richard
Original Assignee
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd filed Critical Tarix Pharmaceuticals Ltd
Publication of BR112016007816A2 publication Critical patent/BR112016007816A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112016007816A 2013-10-11 2014-10-01 composições peptídicas inovadoras BR112016007816A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361890056P 2013-10-11 2013-10-11
US201461940095P 2014-02-14 2014-02-14
PCT/US2014/058646 WO2015054006A2 (en) 2013-10-11 2014-10-01 Novel peptide compositions

Publications (1)

Publication Number Publication Date
BR112016007816A2 true BR112016007816A2 (pt) 2017-12-05

Family

ID=52813728

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007816A BR112016007816A2 (pt) 2013-10-11 2014-10-01 composições peptídicas inovadoras

Country Status (13)

Country Link
EP (1) EP3054967A4 (enExample)
JP (1) JP2017501967A (enExample)
KR (1) KR20160065969A (enExample)
CN (1) CN105828831A (enExample)
AU (1) AU2014332346B2 (enExample)
BR (1) BR112016007816A2 (enExample)
CA (1) CA2926641A1 (enExample)
CL (1) CL2016000836A1 (enExample)
IL (1) IL244956B (enExample)
MX (1) MX2016004660A (enExample)
RU (1) RU2016112931A (enExample)
SG (1) SG11201602661PA (enExample)
WO (1) WO2015054006A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6863362B2 (ja) * 2016-03-03 2021-04-21 不二製油株式会社 神経栄養因子の脳内分泌促進するための食品添加用組成物
EA201991699A1 (ru) * 2017-02-16 2020-01-21 Кареджен Ко., Лтд. Конъюгат салициловой кислоты и пептида

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
DE69738326T2 (de) 1996-07-12 2008-07-03 Mcgill University, Montreal Verbindungen und verfahren zur regulierung der zellanlagerung
WO2001053331A2 (en) 2000-01-24 2001-07-26 Adherex Technologies, Inc. Peptidomimetic modulators of cell adhesion
AU2002335657A1 (en) 2001-08-24 2003-03-10 Neuronz Biosciences, Inc. Neural regeneration peptide and methods for their use in treatment of brain damage
US7563862B2 (en) 2001-08-24 2009-07-21 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use in treatment of brain damage
AU2003293807A1 (en) * 2002-12-24 2004-07-22 Algonomics N.V. Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
EP1685151A4 (en) * 2003-10-31 2009-04-22 Neuren Pharmaceuticals Ltd PEPTIDES FOR THE REGENERATION OF NERVES AND METHOD FOR THEIR APPLICATION IN THE TREATMENT OF BRAIN DAMAGES
WO2007011595A2 (en) 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
WO2012006598A2 (en) * 2010-07-09 2012-01-12 Dana-Farber Cancer Institute, Inc. Stabilized insulinotropic peptides and methods of use
KR20140140546A (ko) * 2012-02-10 2014-12-09 타릭스 파마슈티컬스 엘티디. 말초 혈관 질환의 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
CN105828831A (zh) 2016-08-03
IL244956B (en) 2019-10-31
SG11201602661PA (en) 2016-05-30
KR20160065969A (ko) 2016-06-09
EP3054967A4 (en) 2017-04-19
WO2015054006A2 (en) 2015-04-16
AU2014332346B2 (en) 2019-01-24
CA2926641A1 (en) 2015-04-16
MX2016004660A (es) 2016-11-14
EP3054967A2 (en) 2016-08-17
WO2015054006A3 (en) 2015-06-04
JP2017501967A (ja) 2017-01-19
AU2014332346A1 (en) 2016-05-05
IL244956A0 (en) 2016-05-31
RU2016112931A (ru) 2017-11-16
CL2016000836A1 (es) 2016-09-16
RU2016112931A3 (enExample) 2018-06-20

Similar Documents

Publication Publication Date Title
PL3727460T3 (pl) Bicykliczne ligandy peptydowe swoiste wobec epha2
UY36774A (es) Anticuerpos de enlace-tau
UY34885A (es) Proteínas de unión anti-mesotelina
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
MX370924B (es) Composiciones para modular la expresión de c9orf72.
MX391989B (es) Conjugados de amatoxina y anticuerpos.
MX2017006283A (es) Peptidos macrociclicos utiles como inmunomoduladores.
EA201591137A1 (ru) Ингибиторы mk2 и их применения
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
NZ725568A (en) Modified j-chain
DK3723783T3 (da) Mitokondrie-målrettede peptider
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
EA201790380A1 (ru) Ингибиторы mk2 и их применения
UY36773A (es) Anticuerpos de enlace-tau
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
DK3548058T3 (da) Sammensætninger omfattende peptid wkdeagkplvk
ZA201803551B (en) Personal care composition comprising taurine, arginine, glycine
UY35463A (es) Formulaciones de polipéptido fc-factor ix.
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
JO3456B1 (ar) فيروتيوكسيتين بيروجلوتامات
EA201791716A1 (ru) Фармацевтический состав
IL252902A0 (en) Amino acid and peptide conjugates and their uses
AR097668A1 (es) Colorante-polímero
BR112015005738A2 (pt) formulações orais de angiotensina
GB201612150D0 (en) Modified peptide

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements